Results 41 to 50 of about 7,581 (239)

Safety and efficacy of ceftolozane/tazobactam plus metronidazole versus meropenem from a phase 2, randomized clinical trial in pediatric participants with complicated intra-abdominal infection [PDF]

, 2023
BACKGROUND: Ceftolozane/tazobactam, a cephalosporin-β-lactamase inhibitor combination, is approved for the treatment of complicated urinary tract infections and complicated intra-abdominal infections (cIAI).
Bensaci, Mekki, Bruno, Christopher J, De Anda, Carisa, Dementieva, Nataliia, Huntington, Jennifer A, Jackson, Carl-Christian A, Johnson, Matthew G, Lonchar, Julia, Newland, Jason, Popejoy, Myra W, Rhee, Elizabeth G, Su, Feng-Hsiu   +11 more
core   +2 more sources

Ceftolozane-tazobactam in nosocomial pneumonia

Revista Española de Quimioterapia, 2022
Ceftolozane is a potent antimicrobial against Pseudomonas aeruginosa, including carbapenem-resistant and multidrug-resistant strains, and is also active against Enterobacteriaceae. It MIC (minimal inhibitory concentration) and MPC (mutant preventive concentration) are close together, allowing to avoid the mutant selection window specifically in the ...
Candel, Francisco Javier, del Castillo, Juan González, Jiménez, Agustín Julián, Matesanz, Mayra   +3 more
openaire   +2 more sources

New antimicrobials [PDF]

, 2017
Since 2010 the new antimicrobials introduced have activity against resistant Gram negative bacteria, long half-lives against Gram positive bacteria, better activity against Clostridium difficile, and safer antifungal properties. Limiting factors to using
Roland, Will
core   +1 more source

Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy [PDF]

, 2020
We present a successful treatment, with tigecycline monotherapy, of acute prostatitis caused by multidrug-resistant Escherichia coli harboring an NDM-1 carbapemenase along with a CMY-2 cephalosporinase and a TEM ...
Babouee Flury, Baharak, Buetti, Niccolo, Casanova, Carlo, Furrer, Hansjakob, Jent, Philipp, Livermore, David M, Lo Priore, Elia, Pelzer, Niklas   +7 more
core   +2 more sources

Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

Antimicrobial Resistance and Infection Control, 2017
Background The prevalence of antimicrobial resistance among gram-negative pathogens in complicated intra-abdominal infections (cIAIs) has increased. In the absence of timely information on the infecting pathogens and their susceptibilities, local or ...
Vimalanand S. Prabhu, Joseph S. Solomkin, Goran Medic, Jason Foo, Rebekah H. Borse, Teresa Kauf, Benjamin Miller, Shuvayu S. Sen, Anirban Basu   +8 more
doaj   +1 more source

In vitro activity of ceftolozane/tazobactam against Gram‐negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries—SMART 2017–2019

Journal of Global Antimicrobial Resistance, 2022
Objectives: Antimicrobial resistance is one of the top 10 global public-health threats. Especially high rates of resistance have been reported for isolates from ICU patients, requiring expanded treatment options in this setting. We evaluated the activity
Sibylle H. Lob, Krystyna M. Kazmierczak, Wei-Ting Chen, Fakhar Siddiqui, C. Andrew DeRyke, Katherine Young, Mary R. Motyl, Daniel F. Sahm   +7 more
doaj   +1 more source

P-2305. Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam [C/T] Real-world Analysis Results (SPECTRA): Results of the Immunocompromised Patients [PDF]

Open Forum Infect Dis
Emre Yücel, Àlex Soriano, David L. Paterson, Florian Thalhammer, Stefan Kluge, Pierluigi Viale, Mike Allen, Brune Akrich, Yanbing Zhou, Huina Yang, Sundeep Kaul   +10 more
europepmc   +2 more sources

The Surgical Infection Society revised guidelines on the management of intra-abdominal infection [PDF]

, 2017
Background: Previous evidence-based guidelines on the management of intra-abdominal infection (IAI) were published by the Surgical Infection Society (SIS) in 1992, 2002, and 2010. At the time the most recent guideline was released, the plan was to update
Chang, Phillip K, Diaz, Jose J, Jr, Huston, Jared M, May, Addison K, Mazuski, John E, Mollen, Kevin P, Nadler, Evan P, O\u27Neill, Patrick J, Prince, Jose M, Rosengart, Matthew R, Sawyer, Robert G, Tessier, Jeffrey M   +11 more
core   +3 more sources

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)

Brazilian Journal of Infectious Diseases, 2017
This study evaluated the in vitro activity of ceftolozane-tazobactam and comparator agents tested against Latin American isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients with health care-associated infections.
Michael A. Pfaller, Dee Shortridge, Helio S. Sader, Ana Gales, Mariana Castanheira, Robert K. Flamm   +5 more
doaj   +1 more source

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-2016 [PDF]

, 2017
Background: Ceftazidime/avibactam combines an established oxyimino-cephalosporin with the first diazabicyclooctane β-lactamase inhibitor to enter clinical use.
Doumith, Michel, Hill, Robert, Hopkins, Katie L, Livermore, David M, Meunier, Danièle, Pike, Rachel, Staves, Peter, Woodford, Neil   +7 more
core   +1 more source